Navigation Links
Frost & Sullivan Recognizes Novagali Pharma for Innovation in Ophthalmic Therapies
Date:3/19/2009

ll. Commercialized for sale in France in April 2008 and an expected U.S. launch, Cationorm(R), an over-the-counter (OTC) dry eye treatment developed on the basis of Novasorb technology, is the company's first product from its pipeline to reach the market. The company's other lead drug candidates in development in the U.S. include Cyclokat (NOVA22007), a Novasorb-based therapy in phase III trials for moderate-to-severe dry eye, and Cortiject (NOVA63035), a corticosteroid formulated with Eyeject technology that is in phase I trials for diabetic macular edema.

"The development of new products that operate through novel mechanisms of action is vital to future advancements in ocular drug delivery," stresses Hughes. "Through focused research into novel treatment modalities in ophthalmics, Novagali Pharma's proprietary technology platforms are set to greatly benefit both patients and healthcare practitioners in the near future."

In recognition of Novagali's dedication and pioneering research in this field Frost & Sullivan is proud to present it with the 2009 North American Industry Innovation and Advancement of the Year Award in ocular drug delivery.

Each year, Frost & Sullivan presents this award to the company that has proven to be a leader in the industry and that, through its pioneering technology, sound business strategy, and research efforts, has been successful in moving the state of the industry forward. Its excellence in the field has extended beyond its technical advancements and encompasses a comprehensive view of market participants, resulting in an ongoing improvement in the industry, more comprehensive participation in the industry and for its contributions to the advancement of the market.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as lead
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Frost & Sullivan European Drug Discovery Product Innovation Award Bestowed on Xenometrix AG
2. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
3. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
4. Magellan to Receive Frost & Sullivan 2009 North American Product Innovation Award; Three-Minute LeadCare(R) II Test Identifies Children with Lead Poisoning
5. Frost & Sullivan to Present the 2009 Excellence in Medical Technologies & Life Sciences Awards
6. Frost & Sullivan Recognizes Covidien for Its CT Contrast Delivery System With RFID Enabled Intelligence
7. Frost & Sullivan Lauds BioTrove for Providing Research-Enabling Life Sciences and Drug Discovery Technologies
8. Frost & Sullivans Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells
9. Perceptive Informatics Receives Frost & Sullivan Product Line Strategy Award
10. Pioneer(R) Surgical Technology, Inc. Wins Frost & Sullivans 2009 North American Orthopaedic Tissue Engineering Technology Innovation Award
11. Frost & Sullivan Names Naviscan a Leader in the Future of Molecular Breast Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 Immune Pharmaceuticals Inc., or "Immune" ... Directors has elected Rene-Pierre Azria as a ... Committee, with oversight on strategic and financial transactions. Mr. ... Committee, the Compensation Committee and the Corporate Governance and ... commented: "I have a long-time interest in Life Sciences ...
(Date:4/21/2015)... , April 21, 2015  Novogen Limited (ASX:NRT; ... biotechnology company, advises that it has entered into ... fully-paid ordinary shares plus one attaching 6-month option ... every ordinary share issued, to institutional investors in ... a private placement for aggregate gross proceeds of ...
(Date:4/21/2015)... April 21, 2015 Leading-edge ... clinical applications will be presented at the ... scientists, regulators and clinicians from academia, industry ... sponsored by Invibio Biomaterial Solutions. The world-leading ... specialist in manufacturing and R&D for medical-device ...
(Date:4/20/2015)... April 20, 2015 Stent retriever thrombectomy, ... vessels in the brain reduced disability after stroke, ... Jovin, MD, President of the Society of Vascular ... is a giant step forward that will change ... stroke patients," said Jovin, who is associate professor ...
Breaking Biology Technology:Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 3Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 5Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 62nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 2SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 3
... CV Therapeutics,Inc. (Nasdaq: CVTX ) today announced ... results for 2007 after the market closes on Tuesday,February ... at,5:00 p.m. EST, 2:00 p.m. PST, on the company,s ... on to the Company,s website at, http://www.cvt.com and ...
... In a letter to,Governor Jennifer Granholm today, ... Governor,s State of the State Address,wherein she called ... is the,statewide association for Michigan,s life sciences industry., ... the legislature, to diversify,the state,s economy by focusing ...
... Md., Jan. 30 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: ... commercializing novel anti-infective products, today,announced that it has ... and warrants, resulting in the receipt of $21 ... use the proceeds from the financing to support,the ...
Cached Biology Technology:CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008 2MichBio Responds to Governor's Plan to Repeal Tort Reform Laws 2MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million 2MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million 3
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... that acts as a "master switch" in certain white ... The study, published in the journal Nature Immunology ... diseases such as rheumatoid arthritis that involve excessive inflammation. ... body uses against harmful stimuli such as infections or ...
... WASHINGTON, Jan. 15, 2011 In research described as "a ... reporting that cigarette smoke begins to cause genetic damage within ... Their report, the first human study to detail the ... cancer, appears in Chemical Research in Toxicology , one ...
... 2010) The kidney is made up of roughly 1 ... waste products from the blood, recycle some substances to be ... segment of nephrons, called the distal nephron, helps set blood ... Today scientists at The University of Texas Health ...
Cached Biology News:Scientists find the 'master switch' for key immune cells in inflammatory diseases 2'A stark warning:' Smoking causes genetic damage within minutes after inhaling 2
... Immunogen KLH-conjugated, synthetic ... 54-75 (RRGPHRNPG-PGDDDGQRSRSSS) of mouse p19ARF. ... to amino acids 62-75. Clone ... Routinely evaluated by immunoblot. ...
EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
Complete cell culture media with cytokines...
...
Biology Products: